SCHEMBL1674158

SCHEMBL1674158

CN1Cc2nc(Cl)ccc2C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 11/20 0.42
TDP2 O95551 1/20 0.37
NSD2 O96028 1/20 0.37
GABRG2 P18507 4/20 0.35
GABRB3 P28472 4/20 0.35
GABRA5 P31644 4/20 0.35
GABRA1 P14867 3/20 0.35
GABRA3 P34903 3/20 0.35
GABRA2 P47869 3/20 0.35
GABRA6 Q16445 3/20 0.35
DPP4 P27487 1/20 0.34
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34
HTR3A P46098 1/20 0.34
HTR3D Q70Z44 1/20 0.34
HTR3C Q8WXA8 1/20 0.34
GABRA4 P48169 2/20 0.34
CSNK1D P48730 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29363708 1.00 GRM5 (0.42) GRM5TDP2NSD2GABRG2GABRB3
SCHEMBL3371217 0.83 GRM5 (0.59) GRM5GABRG2GABRB3GABRA5MEN1
SCHEMBL24692829 0.82 GRM5 (0.38) GRM5DPP4MEN1KMT2A
SCHEMBL26713429 0.80 CYP2C19 (0.45) GRM5GABRG2GABRB3GABRA5GABRA1
SCHEMBL29084837 0.79 GRM5 (0.38) GRM5MEN1KMT2A
SCHEMBL30057479 0.78 GRM5 (0.45) GRM5
SCHEMBL30057213 0.78 IDH1 (0.34) TDP2NSD2
SCHEMBL29084747 0.76 BRD9 (0.40) GRM5GABRG2GABRB3GABRA5MEN1
SCHEMBL26141068 0.76 GRM5 (0.36) GRM5MEN1KMT2A
SCHEMBL1673827 0.76 DPP4 (0.40) GRM5GABRA1DPP4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025106949-A1 WRN INHIBITORS RADD PHARMACEUTICALS, INC. (US) 2025-05-22 WO disclosed
CN-117321051-A Compounds as PARP inhibitors 重庆复尚源创医药技术有限公司 2023-12-29 CN disclosed
US-20230348439-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES INC (US) 2023-11-02 US disclosed
US-20230348439-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES INC (US) 2023-11-02 US disclosed
US-11667624-B2 Indole compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2023-06-06 US disclosed
US-11667624-B2 Indole compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2023-06-06 US disclosed
US-20230049406-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. 2023-02-16 US disclosed
WO-2020145250-A1 15-PGDH INHIBITOR 杏林製薬株式会社 2020-07-16 WO disclosed
EP-2299816-B1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME (US) 2013-11-13 EP disclosed
EP-2278969-B1 Inhibitors of Janus kinases MERCK SHARP & DOHME (US) 2013-02-13 EP disclosed
US-8278335-B2 Inhibitors of Janus kinases MERCK SHARP & DOHME CORP. (US) 2012-10-02 US disclosed
US-8278335-B2 Inhibitors of Janus kinases MERCK SHARP & DOHME CORP. (US) 2012-10-02 US disclosed
US-8278335-B2 Inhibitors of Janus kinases MERCK SHARP & DOHME CORP. (US) 2012-10-02 US disclosed
US-20110166129-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-07-07 US disclosed
US-20110166129-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-07-07 US disclosed
US-20110166129-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-07-07 US disclosed
US-20110082136-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-04-07 US disclosed
US-20110082136-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-04-07 US disclosed
US-20110082136-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-04-07 US disclosed
WO-2009155156-A1 INHIBITORS OF JANUS KINASES MERCK & CO., INC. (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049406-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 GRM5 444/4885TDP2 1645/4885NSD2 1544/4885
US-20110082136-A1 INHIBITORS OF JANUS KINASES JAK2, JAK3, JAK1 GRM5 2751/4885TDP2 1722/4885NSD2 2222/4885
US-20230348439-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 GRM5 446/4885TDP2 1702/4885NSD2 1401/4885
US-11667624-B2 Indole compounds as androgen receptor modulators AR, FSHR, ADRB3 GRM5 390/4885TDP2 1526/4885NSD2 1929/4885
US-20110166129-A1 INHIBITORS OF JANUS KINASES JAK2, JAK3, JAK1 GRM5 2751/4885TDP2 1722/4885NSD2 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.